Literature DB >> 28093134

Management of Clostridium difficile Infection in Inflammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute.

Sahil Khanna1, Andrea Shin2, Ciarán P Kelly3.   

Abstract

The purpose of this expert review is to synthesize the existing evidence on the management of Clostridium difficile infection in patients with underlying inflammatory bowel disease. The evidence reviewed in this article is a summation of relevant scientific publications, expert opinion statements, and current practice guidelines. This review is a summary of expert opinion in the field without a formal systematic review of evidence. Best Practice Advice 1: Clinicians should test patients who present with a flare of underlying inflammatory bowel disease for Clostridium difficile infection. Best Practice Advice 2: Clinicians should screen for recurrent C difficile infection if diarrhea or other symptoms of colitis persist or return after antibiotic treatment for C difficile infection. Best Practice Advice 3: Clinicians should consider treating C difficile infection in inflammatory bowel disease patients with vancomycin instead of metronidazole. Best Practice Advice 4: Clinicians strongly should consider hospitalization for close monitoring and aggressive management for inflammatory bowel disease patients with C difficile infection who have profuse diarrhea, severe abdominal pain, a markedly increased peripheral blood leukocyte count, or other evidence of sepsis. Best Practice Advice 5: Clinicians may postpone escalation of steroids and other immunosuppression agents during acute C difficile infection until therapy for C difficile infection has been initiated. However, the decision to withhold or continue immunosuppression in inflammatory bowel disease patients with C difficile infection should be individualized because there is insufficient existing robust literature on which to develop firm recommendations. Best Practice Advice 6: Clinicians should offer a referral for fecal microbiota transplantation to inflammatory bowel disease patients with recurrent C difficile infection.
Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28093134     DOI: 10.1016/j.cgh.2016.10.024

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  34 in total

1.  Risk of Clostridium difficile Infection in Patients With Celiac Disease: A Population-Based Study.

Authors:  Benjamin Lebwohl; Yael R Nobel; Peter H R Green; Martin J Blaser; Jonas F Ludvigsson
Journal:  Am J Gastroenterol       Date:  2017-10-31       Impact factor: 10.864

2.  Current Aspects on Differentiating Relapses from Over-Infections in Symptomatic Inflammatory Bowel Diseases.

Authors:  Christos Liatsos; Apostolis Papaefthymiou; Maria Tzouvala; Michael Doulberis; Evangelia Petridou; Jannis Kountouras
Journal:  Dig Dis Sci       Date:  2019-07-25       Impact factor: 3.199

3.  Does early corticosteroid therapy affect prognosis in IBD patients hospitalized with Clostridioides difficile infection?

Authors:  Haggai Bar-Yoseph; Haneen Daoud; Dana Ben Hur; Yehuda Chowers; Matti Waterman
Journal:  Int J Colorectal Dis       Date:  2020-01-11       Impact factor: 2.571

Review 4.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

5.  Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection.

Authors:  Dipesh Solanky; Darrell S Pardi; Edward V Loftus; Sahil Khanna
Journal:  Inflamm Bowel Dis       Date:  2019-02-21       Impact factor: 5.325

6.  Fecal microbiota transplantation for recurrent Clostridium difficile infection in a patient with ulcerative colitis.

Authors:  Kosaku Nanki; Shinta Mizuno; Katsuyoshi Matsuoka; Keiko Ono; Shinya Sugimoto; Hiroki Kiyohara; Mari Arai; Moeko Nakashima; Kozue Takeshita; Keiichiro Saigusa; Mitsutoshi Senoh; Tadashi Fukuda; Makoto Naganuma; Haru Kato; Wataru Suda; Masahira Hattori; Takanori Kanai
Journal:  Intest Res       Date:  2018-01-18

7.  C. difficile and the Patient with Inflammatory Bowel Disease: A Testing Dilemma.

Authors:  Varun Moktan; Emily Jonica; Zhou Li; Donna Jane Hata; Francis A Farraye
Journal:  Dig Dis Sci       Date:  2021-03       Impact factor: 3.199

8.  Fecal Microbiota Transplantation in Inflammatory Bowel Disease Patients With Clostridium difficile Infection.

Authors:  Ari Grinspan
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-09

9.  Does Obesity Influence the Risk of Clostridium difficile Infection Among Patients with Ulcerative Colitis?

Authors:  Sajiv Chandradas; Hamed Khalili; Ashwin Ananthakrishnan; Connor Wayman; Warren Reidel; Jill Waalen; Gauree G Konijeti
Journal:  Dig Dis Sci       Date:  2018-05-19       Impact factor: 3.199

Review 10.  Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology.

Authors:  Alexander Khoruts; Christopher Staley; Michael J Sadowsky
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-08-25       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.